Key Insights on Gross Profit: Johnson & Johnson vs Perrigo Company plc

Johnson & Johnson's dominance over Perrigo in gross profit growth.

__timestampJohnson & JohnsonPerrigo Company plc
Wednesday, January 1, 2014515850000001447700000
Thursday, January 1, 2015485380000001712400000
Friday, January 1, 2016502050000002051800000
Sunday, January 1, 2017510960000001979500000
Monday, January 1, 2018544900000001831500000
Tuesday, January 1, 2019545030000001773300000
Wednesday, January 1, 2020541570000001815200000
Friday, January 1, 2021553380000001416200000
Saturday, January 1, 2022553940000001455400000
Sunday, January 1, 2023586060000001680400000
Monday, January 1, 202433879000000
Loading chart...

Unleashing the power of data

A Tale of Two Giants: Johnson & Johnson vs. Perrigo Company plc

In the ever-evolving landscape of the pharmaceutical industry, the financial health of companies is a key indicator of their market position and potential for growth. Over the past decade, Johnson & Johnson has consistently demonstrated its dominance with a gross profit that has grown by approximately 14% from 2014 to 2023. In contrast, Perrigo Company plc, while maintaining a steady course, has seen a more modest increase of around 16% in the same period.

Johnson & Johnson's gross profit peaked in 2023, reaching nearly 5.9 times that of Perrigo's. This stark difference highlights the scale and efficiency of Johnson & Johnson's operations. As the industry continues to face challenges and opportunities, these insights provide a glimpse into the strategic maneuvers of these two pharmaceutical powerhouses.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025